Modulators of indoleamine 2,3-dioxygenase and methods of using the same
申请人:Combs P. Andrew
公开号:US20060258719A1
公开(公告)日:2006-11-16
The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.
本发明涉及色氨酸2,3-二氧化酶(IDO)的调节剂,以及其组合物和药用方法。
Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model
作者:Eddy W. Yue、Brent Douty、Brian Wayland、Michael Bower、Xiangdong Liu、Lynn Leffet、Qian Wang、Kevin J. Bowman、Michael J. Hansbury、Changnian Liu、Min Wei、Yanlong Li、Richard Wynn、Timothy C. Burn、Holly K. Koblish、Jordan S. Fridman、Brian Metcalf、Peggy A. Scherle、Andrew P. Combs
DOI:10.1021/jm900518f
日期:2009.12.10
Testing of 5l in mice demonstrated pharmacodynamic inhibition of IDO, as measured by decreased kynurenine levels (>50%) in plasma and dose dependent efficacy in mice bearing GM-CSF-secreting B16 melanoma tumors.
在吲哚胺2,3-二加氧酶(IDO)的新型抑制剂中,已发现羟am的化学型是关键药效团。优化导致鉴定出5l,这是IDO的一种有力(HeLa IC 50 = 19 nM)竞争性抑制剂。小鼠中5l的测试证明IDO具有药效学抑制作用,这是通过血浆中犬尿氨酸水平降低(> 50%)和携带分泌GM-CSF的B16黑色素瘤肿瘤的小鼠的剂量依赖性功效来衡量的。
MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME
申请人:Combs Andrew P.
公开号:US20110311479A1
公开(公告)日:2011-12-22
The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.
本发明涉及吲哚胺2,3-二氧化酶(IDO)的调节剂,以及其组成物和制药方法。
Ring formation reactions of 4-aminofurazan-3-carboxyamidoximfs